1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Copper Mining Market in Asia-Pacific to 2020

Stribild Introduction to Reinforce HIV/AIDS Revenues as Key Patents Expire

 
PRLog - Nov. 20, 2012 - Gilead Science’s combination drug Stribild (previously known as the “Quad pill”) is expected to bolster the HIV/AIDS therapeutics market as a number of significant medications go off-patent over the next few years, states business intelligence provider.

Forecasts from the firm’s latest report indicate that the global HIV/AIDS therapeutics market will increase in value at a Compound Annual Growth Rate (CAGR) of 7% between the years 2011 and 2018, from $13.5 billion to $21.8 billion.

As a consequence of the on-going patent-cliff, this predicted growth rate is less than the market experienced in previous years. Between 2004 and 2011, the market experienced a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva and Reyataz (both produced by Bristol-Myers Squibb) in 2014 and 2017 respectively, a more modest increase is predicted.

However, the market is not without promise. The multi-class fixed dose combination tablet from Gilead Sciences, Atripla, saw global revenue increase from $2.9 billion in 2010 to $3.2 billion last year, while potential blockbuster Stribild was approved by the US Food and Drug Administration in August of this year and is expected to make a major impact.

Gilead announced Stribild's initial price as $28,500, which is one-third greater than that of Atripla, but with impressive efficacy and strong patient compliance, We do not expect this higher cost to be a significant barrier to widespread use.

Last year’s sales figures show Gilead as being the greatest revenue shareholder of the world’s top seven markets, with 36%. With less than half of that number, Bristol-Myers Squibb came second with 16%, while ViiV Healthcare completed the top three with a 13% segment.

This report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018.

For Sample Pages, please click or add the below link to your browser:

http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?...

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our  team of industry experts.

We are market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.


Visit our Report Store

http://www.globalmarketsdirect.com

For more details contact:

pressreleases@globalmarketsdirect.com (mailto:pressreleases@globalmarketsdirect.com%20)

--- End ---

Click to Share

Contact Email:
***@globalmarketsdirect.com Email Verified
Source:Global Markets Direct
Phone:+914066166782
Zip:EC4Y 0AN
State/Province:London - United Kingdom
Industry:Marketing
Tags:Global Markets Direct, market research, metal and mining, copper mining market
Shortcut:prlog.org/12027855
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share